DXB released its quarterly update and thanks to a successful capital raising during the quarter the company has a healthy net cash balance of $6.8m. This is sufficient capital to fund its ongoing programs. The company is expected to announce the top-line results from its DMX-200 FSGS Stage 2a clinical study and treat the final patient in its Stage 2 Diabetic Kidney Disease study by the end of the month with readout expected shortly thereafter. The recently announced DMX-200 Covid-19 Pandemic Study sponsored by the World Health Organisation (WHO) is ongoing. We are positive on the company’s outlook and maintain our SPEC BUY recommendation and price target of $0.72.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.
